Hola,
¿eres nuevo aquí?

Regístrate gratis y conecta tu empresa con financiación pública, partners y proyectos.

Tengo cuenta

Regístrate

Ver video

HEART-iPS

Financiado

Cerrado

Congenital heart disease associated arrhythmia deciphering Hamamy syndrome nove...

Congenital heart disease associated arrhythmia deciphering Hamamy syndrome novel rare disease using iPS cells In the growing population of patients with congenital heart defects (CHD), while arrhythmias are not a major issue for children, they are a leading complication during adulthood. My hypothesis is that the origin of some life-threa... ver más

31/08/2015

CNRS

180K€

Presupuesto del proyecto: 180K€

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Fecha límite participación Sin fecha límite de participación.

Ver 2 Participantes

Financiación concedida El organismo FP7 notifico la concesión del proyecto el día 2015-08-31 No tenemos la información de la convocatoria

0% 100% 100%

Información adicional privada

No hay información privada compartida para este proyecto. Habla con el coordinador.

2 Participantes

CNRS

0.00€ | Lider

N.D. | Participante

Proyectos interesantes

SAF2013-45543-R

Medical Technol...

Applied Physics

484K€ Cerrado

SAF2016-78370-R

Medical Technol...

Applied Physics

484K€ Cerrado

CHD-IPS

Medical Technol...

Data Science

1M€ Cerrado

SAF2017-88116-P

Medical Technol...

Applied Physics

218K€ Cerrado

SAF2011-30112

Medical Technol...

Applied Physics

97K€ Cerrado

PID2019-110155RA-I00

Medical Technol...

Applied Physics

109K€ Cerrado

Conecta tu I+D

¿Tienes un proyecto y buscas un partner? Gracias a nuestro motor inteligente podemos recomendarte los mejores socios y ponerte en contacto con ellos. Te lo explicamos en este video

Líder del proyecto

CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE... No se ha especificado una descripción o un objeto social para esta compañía.

TRL 4-5

Presupuesto del proyecto 180K€

Fecha límite de participación Sin fecha límite de participación.

Descripción del proyecto In the growing population of patients with congenital heart defects (CHD), while arrhythmias are not a major issue for children, they are a leading complication during adulthood. My hypothesis is that the origin of some life-threatening arrhythmias in adult, lies in cardiac structural and electrophysiological development. Thus, studying causes of CHDs may reveal key steps, mis-regulated in adult patients with CHD, leading to arrhythmias. Cardiac development and adult electrical function are finely regulated by transcription factors (TFs). Mutations in TFs have previously been linked to patients with CHD who are developing arrhythmias in adulthood. Hamamy syndrome is a newly described rare disease with CHD and rhythm disorders, caused by a mutation in IRX5 TF. In adult mice, Irx5 is known to regulate cardiac electrical function. I hypothesize that IRX5 mutation in Hamamy-affected patients, leads to misregulation of heart development, promoting arrhythmic events during adulthood. I already generated induced pluripotent stem (iPS) cells from Hamamy patients and a transgenic mouse expressing the Irx5 mutation. The project will be focused on three aims: 1. Characterizing the cardiac cellular function altered by IRX5 mutation, using iPS-derived cardiomyocytes; 2. Identifying cardiac structural and electrophysiological defects in the transgenic mouse; 3. Understanding the syndrome’s molecular mechanism. This study will provide immediate insight into understanding fundamental processes by which some arrhythmias in the adult originate in cardiac development. It may also help unveil the mechanism of age-related increase of arrhythmias in the general population. Finally, it will illustrate the ability of human iPS cell technology to model the abnormal functional phenotype of an inherited cardiac disorder. As such, it represents a promising model to study disease mechanisms, optimize patient care (personalized medicine), and aid in the development of new therapies.

Conecta tu I+D

Entra hoy

¿Olvidé mi contraseña?

Financiación

Empresas

CTIs/Universidades

Proyectos

Investigadores